UNSPSC 51172168: Difenoximide hydrochloride

This classification denotes an antispasmotic agent with the molecular formula C32H31N3O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6GEY4W769K, chemically known as 1-piperidinebutanenitrile, 4-(((2,5-dioxo-1-pyrrolidinyl)oxy)carbonyl)-alpha,alpha,4-triphenyl-, monohydrochloride but more generally known as difenoximide hydrochloride, which bears US NIH Compound Identifier 71431. Most nations, for tariff and trade purposes, schedule difenoximide hydrochloride under HS 29333999 and SITC 51574.

As of Q4 2014, DIFENOXIMIDE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Difenoximide hydrochloride bears US NLM NCI C77288. SMILES: C1CCC(CC1)C2(CCN(CC2)CCC(C#N)(C3CCCCC3)C4CCCCC4)C(=O)ON5C(=O)CCC5=O.CL.

UNSPSC 51172168 Difenoximide hydrochloride is a Commodity code that encompasses specific pharmaceutical active ingredients and chemical compounds procured by state and local health, criminal justice, and human services agencies. Based on recent solicitation activity, state and local governments use this code to source pharmaceutical and testing-related products for correctional supervision, pharmacy benefit programs, and multistate cooperative purchasing arrangements. The issuing bodies include county community supervision departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of multiple participating jurisdictions.

Recent activity shows Collin County Community Supervision and Corrections Department issued RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026; the Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, with contracts effective July 1, 2026 and extending through June 30, 2028. The geographic spread centers on Texas and Minnesota, with MMCAP purchasing serving multiple states including Oregon. The code shows moderate recent activity focused on correctional drug testing and pharmacy benefit procurement rather than narrow chemical sourcing.